Navigation Links
Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
Date:7/16/2009

ZURICH, July 16 /PRNewswire/ -- An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received a second orphan drug designation in the US only weeks after a first designation was granted. The recent designation relates to Burkholderia cepacia pathogens that can cause lethal infections in cystic fibrosis patients. For Axentis Pharma AG of Zurich, Switzerland, both designations affirm the therapeutic potential of its product candidate Fluidosomes(TM)-tobramycin, whose unique microbiological profile sets it apart from other antibiotic formulations (including free tobramycin).

Axentis Pharma (Switzerland) announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted a second orphan drug designation to its lead product candidate Fluidosomes(TM)-tobramycin. This drug is a liposomal formulation of tobramycin and an innovative treatment for infections of the respiratory tract in patients with cystic fibrosis. Only three months ago, the FDA granted Fluidosomes(TM)-tobramycin orphan drug designation for the treatment of pulmonary infections caused by Pseudomonas aeruginosa. The newly granted second designation relates to pulmonary infections caused by Burkholderia cepacia (B. cepacia) pathogens.

Despite stringent infection control practices, B. cepacia infections still occur in cystic fibrosis patients and can lead to fatal sepsis. The cell envelopes of these especially virulent bacteria are impermeable to most antibiotics, which makes them particularly difficult to treat. Due to its unique mode of action, which allows the antibiotics to penetrate into the bacteria, Fluidosomes(TM)-tobramycin could become a particularly effective treatment for B. cepacia infections.

Prof. Dr. Miguel A Valvano, MD, Medical Advisor to Axentis Pharma, comments on the development: "Burkholderia cepacia is almost always mu
'/>"/>

SOURCE Axentis Pharma AG
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Promising Cystic Fibrosis Compound on Track for Development
2. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
3. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
4. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
5. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
6. Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting
7. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
8. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
9. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
10. Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
11. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Colo. , May 24, 2013  Heska Corporation (NASDAQ: ... diagnostic and specialty products, announced today that Dr. ... officer, and Jason Napolitano , executive vice ... Annual Marcum MicroCap Conference, which is being held May 30, ... the Grand Hyatt Hotel. The Company,s presentation ...
(Date:5/24/2013)... The potential of the pulmonary route as ... has been receiving undeniable attention with the recent advances ... crucial formulation considerations for orally inhaled products together with ... in the efficiency of pulmonary delivery, and great strides ... techniques and devices in recent years. With ...
(Date:5/23/2013)... , May 23, 2013 Neurocrine Biosciences, Inc. ... Kevin Gorman , President and Chief Executive Officer of ... th Annual dbAccess Health Care Conference in Boston.   ... 30 at 11:20 a.m. Eastern Time / 8:20 a.m. Pacific ... on the Company,s website at http://www.neurocrine.com . ...
Breaking Medicine Technology:Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2
... (Nasdaq: IDIX ) announced today that Idenix management ... Small Cap Healthcare Conference on Tuesday, September 14, 2010 at ... City and at the Stifel Nicolaus Healthcare Conference on Thursday, ... Seasons Hotel, Boston. The live and archived ...
... YORK, Sept. 7 Reportlinker.com announces that a ... catalogue: Cell Therapy - Technologies, ... SummaryThis report describes ... have already started to play an important role ...
Cached Medicine Technology:Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 2Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 3Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 4Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 5Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 6Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 7Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 8Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 9Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 10Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 11Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 12Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 13Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 14Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 15Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 16Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 17Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 18Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 19Reportlinker Adds Cell Therapy - Technologies, Markets and Companies 20
(Date:5/25/2013)... May 25, 2013 The latest ... from irritable bowel syndrome (IBS) to bloating, constipation, ... the most long-lasting, embarrassing, frustrating and difficult health ... for digestive health have provided a cure ... many factors contributing to digestive health issues, a ...
(Date:5/25/2013)... 25, 2013 According to a ... Market, 2013–2018", published by MarketsandMarkets is expected to ... of 5.54% which analyzes and studies the major ... Europe, Asia, and Rest of the World. , ... Tables , 87 Figures , ...
(Date:5/25/2013)... BC (PRWEB) May 25, 2013 According ... the most beautiful and powerful women that ever lived. ... felt by some of the most powerful men in ... many beauty remedies to keep her skin glowing and ... made with bees- wax, maringa oil and cyprus grass. ...
(Date:5/25/2013)... Los Angeles, CA (PRWEB) May 25, 2013 ... will grow at an average annual rate of 28.7% ... growth of 17.9% in 2013. From 2002 and 2008, no ... analyst Kevin Culbert, causing relatively modest growth during that period. ... (FDA) has approved six new products. This factor contributed to ...
(Date:5/25/2013)... 25, 2013 Ayurveda is the ... wisdom of life". While a medical science, its scope enters ... consciousness. Its fundamental philosophy is that disease is the end ... order to re-establish optimal health, one must discover where we ... style which brings us back into perfect harmony. , The ...
Breaking Medicine News(10 mins):Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Fundamentos de Ayurveda in Mexico (Ayurvedic Principles) Offered by Escuela de Ayurveda de California 2
... A new national plan of action provides a roadmap for ... and often unrecognized brain condition that affects approximately seven million ... to Bring an Ancient Disease into the 21st Century," written ... supplement to the Nov. 2011 issue of the Journal ...
... InDevR, a Boulder-based biotechnology company that develops ... of viruses and other microorganisms, announced today the ... a colorimetric detection system that incorporates core technology ... Office, will enhance laboratories around the world by ...
... News) -- One in 12 teens deliberately harm themselves, but ... young adults, a new study shows. Self-harm, which includes ... suicide and is especially common among females aged 15 to ... , where the finding appears Nov. 16 online. In ...
... Goodwin HealthDay Reporter , WEDNESDAY, Nov. 16 (HealthDay News) ... becoming obese adults at higher risk of type 2 diabetes, high ... But if they manage to get their weight under control ... of those health problems than people who were normal weight all ...
... (HealthDay News) -- A new study offers further evidence that ... research found that unsaturated fats from foods such as avocados, ... insulin. Reduced insulin action can lead to diabetes, which is ... three different types of balanced diets consumed by 164 people ...
... at the University of California, San Diego School of Medicine ... a specific sugar molecule with a pair of cell-killing drugs ... themselves, a process called apoptosis or programmed cell death. ... Research. "The goal of targeted therapy is to ...
Cached Medicine News:Health News:Protecting our brains: Tackling delirium 2Health News:Protecting our brains: Tackling delirium 3Health News:Indevr launches breakthrough colorimetric detection for microarrays using core technology from CU 2Health News:One in 12 Teens Engages in Self-Harm: Report 2Health News:Outlook Good for Obese Kids Who Lose Weight 2Health News:Outlook Good for Obese Kids Who Lose Weight 3Health News:Even Without Weight Loss, Mediterranean Diet Helps Heart: Study 2Health News:New drug combo targets multiple cancers 2
... Professional Package is the best ... laboratory. The package includes the ... additional mounting blocks, v-block adapter, ... a sapphire blade for the ...
... Plus Sectioning System provides a versatile means ... plant tissues. The 3000 employs a ... freezing or embedding. The creation of ... of enzyme activities, and other deleterious effect ...
... The Vibratome 1500 Sectioning System provides a ... animal, or plant tissues. The 1500 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
These specialty razor blades are feather thin and very sharp. Most users have found an increased quality level in Vibratome sections with these blades....
Medicine Products: